Biomaterial Database

Secukinumab therapy in reactive arthritis: Report of two cases. 2022

Prasanta Padhan, and Debashis Maikap

Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India.

Reactive arthritis (ReA) is an immune-mediated aseptic synovitis resulting either from genitourinary or gastrointestinal tract, commonly presenting as oligoarthritis of the lower limbs and rarely urethritis and conjunctivitis. The treatment options include nonsteroidal anti-inflammatory drugs, conventional disease-modifying antirheumatic drugs, and biologics in severe cases. We report successful use of secukinumab in two cases of chronic severe ReA who initially failed to treatment with tumour necrosis factor inhibitor.

UI	MeSH Term	Description	Entries
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000079424	Tumor Necrosis Factor Inhibitors	Compounds or agents that bind to and inhibit the synthesis or activity of TUMOR NECROSIS FACTOR-alpha. Such agents are used to treat inflammatory bowel diseases and other inflammatory diseases.	TNF Antagonist,TNF Blocker,TNF Inhibitor,Tumor Necrosis Factor Antagonist,Tumor Necrosis Factor Blocker,Tumor Necrosis Factor Inhibitor,Tumor Necrosis Factor-a (TNF-a) Antagonist,Tumor Necrosis Factor-a (TNF-a) Blocker,Tumor Necrosis Factor-a (TNF-a) Inhibitor,TNF Antagonists,TNF Blockers,TNF Inhibitors,Tumor Necrosis Factor Antagonists,Tumor Necrosis Factor Blockers,Tumor Necrosis Factor-a (TNF-a) Antagonists,Tumor Necrosis Factor-a (TNF-a) Blockers,Tumor Necrosis Factor-a (TNF-a) Inhibitors,Antagonist, TNF,Antagonists, TNF,Blocker, TNF,Blockers, TNF,Inhibitor, TNF,Inhibitors, TNF
D016918	Arthritis, Reactive	An aseptic, inflammatory arthritis developing secondary to a primary extra-articular infection, most typically of the GASTROINTESTINAL TRACT or UROGENITAL SYSTEM. The initiating trigger pathogens are usually SHIGELLA; SALMONELLA; YERSINIA; CAMPYLOBACTER; or CHLAMYDIA TRACHOMATIS. Reactive arthritis is strongly associated with HLA-B27 ANTIGEN.	Arthritis, Postinfectious,Arthritis, Post-Infectious,Post-Infectious Arthritis,Postinfectious Arthritis,Reactive Arthritis,Reiter Disease,Reiter Syndrome,Reiter's Disease,Reiter's Syndrome,Arthritis, Post Infectious,Post Infectious Arthritis,Post-Infectious Arthritides,Postinfectious Arthritides,Reactive Arthritides,Reiters Disease,Reiters Syndrome
D061067	Antibodies, Monoclonal, Humanized	Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.	Antibodies, Humanized,Humanized Antibodies
D018501	Antirheumatic Agents	Drugs that are used to treat RHEUMATOID ARTHRITIS.	Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents